+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 12Years +
All Genders
ID07689188

Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Adolescents and Adults with Hidradenitis Suppurativa

Led by Harrison Dermatology · Updated on 2026-10-13

10

Participants Needed

1

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a topical medication called roflumilast foam 0.3% in adolescents and adults with Hidradenitis Suppurativa HS, a chronic inflammatory skin condition causing painful lumps and abscesses in areas like the underarms, groin, and buttocks. This phase 2 study focuses on patients with mild to moderate HS Hurley Stage I or II and aims to assess treatment outcomes over 16 weeks. Participants will apply the investigational roflumilast 0.3% topical foam once daily to all active HS lesions for the duration of 16 weeks. The study is open-label with a single group receiving the same treatment. No placebo or comparator group is involved. Patients must avoid certain antibiotics, steroids, and topical antiseptics during the study, and females of childbearing potential must use effective contraception. Throughout the trial, participants will be monitored for changes in the number of abscesses and inflammatory nodules from baseline to week 16. Safety and adherence will be assessed through clinical evaluations, including physical exams and pregnancy tests when applicable. The total study duration per participant is 16 weeks, with scheduled visits to track progress and response to the topical treatment.

CONDITIONS

Brief Title

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

Research Team

H

Harrison P Nguyen, MD, MBA, MPH, FAAD, DTM&H

R

Research Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here